Article Details

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel ...

Retrieved on: 2021-04-08 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel .... View article details on hiswai:

Excerpt

“Our CLDN6 monoclonal antibody exhibits best-in-class target selectivity,” said Benjamin Doranz, Ph.D., chief executive officer of Integral Molecular.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up